Purchase this article with an account.
Jay S. Pepose, Mujtaba A. Qazi; A Three Arm Prospective Clinical Comparison of Three FDA-Approved Presbyopia-Correcting Intraocular Lenses. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1368.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare visual outcomes and quality of vision metrics with 3 FDA-approved presbyopia-correcting IOLs.
This was a prospective, randomized, partially masked, post-market study of 3 IOLs designed to improve distance, intermediate and near vision. The primary efficacy outcome was the Logarithm of the Mean of Mesopic Contrast Sensitivity (without glare at five spatial frequencies). Secondary effectiveness endpoints include high and low contrast VA, UCDVA, UCIVA, UCNVA (16 and 32 inches), optical scatter, depth of focus, visual quality metrics, glare meter, and subject satisfaction.
Crystalens AO has better uncorrected and distance corrected intermediate vision than Tecnis MF or ReSTOR 3.0. Tecnis MF and ReSTOR 3.0 have better distance corrected near vision than Crystalens AO and required lower add for BCNVA. Crystalens AO has less halos than Tecnis MF. Tecnis MF and ReSTOR 3.0 had ~50% higher scatter index than Crystalens AO. Crystalens had narrower 50% and 10% PSF than ReSTOR 3.0 or Tecnis MF.
Each presbyopia-correcting IOL has exploited diverse strategies to enhance depth of focus. These are associated with different compromises with regard to near and intermediate visual acuity, halos, optical scatter and other aspects of visual quality.
Clinical Trial: :
This PDF is available to Subscribers Only